Literature DB >> 30542906

Gene Therapy for Neurodegenerative Diseases.

Vivek Sudhakar1, R Mark Richardson2.   

Abstract

Gene therapy has the potential to provide therapeutic benefit to millions of people with neurodegenerative diseases through several means, including direct correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. Therapeutic efficacy is therefore dependent on knowledge of the disease pathogenesis and the required temporal and spatial specificity of gene expression. An additional critical challenge is achieving the most complete transduction of the target structure while avoiding leakage into neighboring regions or perivascular spaces. The gene therapy field has recently entered a new technological era, in which interventional MRI-guided convection-enhanced delivery (iMRI-CED) is the gold standard for verifying accurate vector delivery in real time. The availability of this advanced neurosurgical technique may accelerate the translation of the promising preclinical therapeutics under development for neurodegenerative disorders, including Parkinson's, Huntington's, and Alzheimer's diseases.

Entities:  

Keywords:  Alzheimer’s disease; Gene therapy; Huntington’s disease; Parkinson’s disease; intraoperative MRI.; viral vector

Mesh:

Year:  2019        PMID: 30542906      PMCID: PMC6361055          DOI: 10.1007/s13311-018-00694-0

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  67 in total

1.  Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey.

Authors:  V E Koliatsos; H J Nauta; R E Clatterbuck; D M Holtzman; W C Mobley; D L Price
Journal:  J Neurosci       Date:  1990-12       Impact factor: 6.167

2.  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.

Authors:  Gabriele Mittermeyer; Chadwick W Christine; Kathryn H Rosenbluth; Suzanne L Baker; Philip Starr; Paul Larson; Paul L Kaplan; John Forsayeth; Michael J Aminoff; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-04-10       Impact factor: 5.695

3.  Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Authors:  Stéphane Palfi; Jean Marc Gurruchaga; G Scott Ralph; Helene Lepetit; Sonia Lavisse; Philip C Buttery; Colin Watts; James Miskin; Michelle Kelleher; Sarah Deeley; Hirokazu Iwamuro; Jean Pascal Lefaucheur; Claire Thiriez; Gilles Fenelon; Cherry Lucas; Pierre Brugières; Inanna Gabriel; Kou Abhay; Xavier Drouot; Naoki Tani; Aurelie Kas; Bijan Ghaleh; Philippe Le Corvoisier; Patrice Dolphin; David P Breen; Sarah Mason; Natalie Valle Guzman; Nicholas D Mazarakis; Pippa A Radcliffe; Richard Harrop; Susan M Kingsman; Olivier Rascol; Stuart Naylor; Roger A Barker; Philippe Hantraye; Philippe Remy; Pierre Cesaro; Kyriacos A Mitrophanous
Journal:  Lancet       Date:  2014-01-10       Impact factor: 79.321

4.  Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors.

Authors:  Xiaomin Su; Adrian P Kells; Ernesto A Salegio; Ernesto Aguilar Salegio; R Mark Richardson; Piotr Hadaczek; Janine Beyer; John Bringas; Philip Pivirotto; John Forsayeth; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

5.  Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease.

Authors:  Biplob Dass; C Warren Olanow; Jeffrey H Kordower
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

6.  Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates.

Authors:  Dali Yin; Francisco E Valles; Massimo S Fiandaca; John Bringas; Francisco Gimenez; Mitchel S Berger; John Forsayeth; Krystof S Bankiewicz
Journal:  Neuroimage       Date:  2009-09-15       Impact factor: 6.556

7.  Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.

Authors:  C W Christine; P A Starr; P S Larson; J L Eberling; W J Jagust; R A Hawkins; H F VanBrocklin; J F Wright; K S Bankiewicz; M J Aminoff
Journal:  Neurology       Date:  2009-10-14       Impact factor: 9.910

8.  Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.

Authors:  Louisa C Johnston; Jamie Eberling; Philip Pivirotto; Piotr Hadaczek; Howard J Federoff; John Forsayeth; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

9.  AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.

Authors:  J Miniarikova; V Zimmer; R Martier; C C Brouwers; C Pythoud; K Richetin; M Rey; J Lubelski; M M Evers; S J van Deventer; H Petry; N Déglon; P Konstantinova
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

10.  Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease.

Authors:  Jana Miniarikova; Ilaria Zanella; Angelina Huseinovic; Tom van der Zon; Evelyn Hanemaaijer; Raygene Martier; Annemart Koornneef; Amber L Southwell; Michael R Hayden; Sander J van Deventer; Harald Petry; Pavlina Konstantinova
Journal:  Mol Ther Nucleic Acids       Date:  2016-03-22       Impact factor: 10.183

View more
  23 in total

1.  A New Era for Surgical Neurotherapeutics.

Authors:  R Mark Richardson; Taylor J Abel
Journal:  Neurotherapeutics       Date:  2019-01       Impact factor: 7.620

2.  Resveratrol Delivery via Gene Therapy: Entering the Modern Era

Authors:  Gurinder Singh
Journal:  Turk J Pharm Sci       Date:  2022-02-28

3.  Systems Biology to Address Unmet Medical Needs in Neurological Disorders.

Authors:  Masha G Savelieff; Mohamed H Noureldein; Eva L Feldman
Journal:  Methods Mol Biol       Date:  2022

Review 4.  Proteinopathies associated to repeat expansion disorders.

Authors:  Anthony Fourier; Isabelle Quadrio
Journal:  J Neural Transm (Vienna)       Date:  2022-01-24       Impact factor: 3.575

Review 5.  GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches.

Authors:  Giulietta M Riboldi; Alessio B Di Fonzo
Journal:  Cells       Date:  2019-04-19       Impact factor: 6.600

6.  Lentiviral vector-mediated transduction of adult neural stem/progenitor cells isolated from the temporal tissues of epileptic patients.

Authors:  Sara Abdolahi; Azizollah Khodakaram-Tafti; Hadi Aligholi; Saeid Ziaei; Maryam Khaleghi Ghadiri; Walter Stummer; Ali Gorji
Journal:  Iran J Basic Med Sci       Date:  2020-03       Impact factor: 2.699

7.  Alzheimer's disease drug development pipeline: 2021.

Authors:  Jeffrey Cummings; Garam Lee; Kate Zhong; Jorge Fonseca; Kazem Taghva
Journal:  Alzheimers Dement (N Y)       Date:  2021-05-25

Review 8.  Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets.

Authors:  Somin Kwon; Michiyo Iba; Changyoun Kim; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

Review 9.  Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach.

Authors:  Matteo Bordoni; Eveljn Scarian; Federica Rey; Stella Gagliardi; Stephana Carelli; Orietta Pansarasa; Cristina Cereda
Journal:  Int J Mol Sci       Date:  2020-05-04       Impact factor: 5.923

Review 10.  Adeno-Associated Viral Vectors in Neuroscience Research.

Authors:  David L Haggerty; Gregory G Grecco; Kaitlin C Reeves; Brady Atwood
Journal:  Mol Ther Methods Clin Dev       Date:  2019-11-26       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.